The tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2

Cancer Research

Volumn 57, Issue 12, 1997, Pages 2434-2434

  Palumbo, Giuseppe A ^a   Yarom, Nirit ^b   Gazit, Aviv ^c   Sandalon, Ziv ^b   Baniyash, Michal ^c   Kleinberger Doron, Nurit ^c   Levitzki, Alexander ^c   Ben Yehuda, Dina ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; TYRPHOSTIN; ADENOSINE TRIPHOSPHATE; CARRIER PROTEIN; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; NITRILE; NUCLEIC ACID SYNTHESIS INHIBITOR; PHENOL DERIVATIVE; PROTEIN BCL 2; PROTEIN P16INK4A; PROTEIN SERINE THREONINE KINASE; TYRPHOSTIN AG17;

APOPTOSIS; ARTICLE; CELL DEATH; ENZYME INHIBITION; GENE TRANSLOCATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; KERATINOCYTE; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; CELL CULTURE; CELL CYCLE G1 PHASE; CELL SURVIVAL; DRUG EFFECT; LYMPHOMA; METABOLISM; PHOSPHORYLATION;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; CARRIER PROTEINS; CDC2-CDC28 KINASES; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; G1 PHASE; HUMANS; LYMPHOMA; NITRILES; NUCLEIC ACID SYNTHESIS INHIBITORS; PHENOLS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0031570414     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Ullrich, A., and Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell, 61: 203-212, 1990.
2. Richardson, J. M., Morla, A. O., and Wang, J. Y. J. Reduction of protein tyrosine phosphorylation during differentiation of human leukemia cell line K-562. Cancer Res., 47: 4066-4070, 1987.
3. Frank, D. A., and Sartorelli, A. C. Alterations in tyrosine phosphorylation during the granulocytic maturation of HL-60 leukemia cells. Cancer Res., 48: 52-58, 1988.
4. Knox, K. A., and Gordon, J. Protein tyrosine phosphorylation is mandatory for CD40-mediated rescue of germinal center B cells from apoptosis. Eur. J. Immunol., 23: 2578-2584, 1993.
5. Otani, H., Erdos, M., and Leonard, W. J. Tyrosine kinase(s) regulate apoptosis and bcl-2 expression in a growth factor-dependent cell line. J. Biol. Chem., 268: 22733-22736, 1993.
6. Bishop, J. M. The molecular genetics of cancer. Science (Washington DC), 235: 305-311, 1987.
7. Ross, R. Platelet derived growth factor. Lancet, 1: 1179-1189, 1989.
8. Elder, J. T., Fisher, G. J., Lindquist, P. B., Bennet, G. L., Pittelkow, M. R., Coffey, R. J., Ellingsworth, L., Denrynck, R., and Voorhees, J. J. Overexpression of transforming growth factor a in psoriatic epidermis. Science (Washington DC), 243: 811-814, 1989.
9. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
10. Levitzki, A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J., 6: 3275-3282, 1992.
11. Toi, M., Mukaida, H., Wada, T., Hirabyashi, N., Toge, T., Hori, T., and Umezawa, K. Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice. Eur. J. Cancer, 26: 722-724, 1990.
12. Yoneda, T., Lyall, R., Asline, M. M., Pearsons, P. E., Spada, A. P., Levitzki, A., Zilberstein, A., and Mundy, G. R. The antiproliferative effects of tyrosine kinase inhibitor tyrphostin on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res., 51: 4430-4435, 1991.
13. Anafi, M., Gazit, A., Gilon, C., Ben-Neriah, Y., and Levitzki, A. Tyrphostin induced differentiation of mouse erythroleukemia cells. FEBS Lett., 330: 260-264, 1993.
14. Anafi, M., Gazit, A., Zehavi, A., Ben-Neriah, Y., and Levitzki, A. Tyrphostin induced inhihition of p210 bcr/abl tyrosine kinase activity induces K562 to differentiate. Blood, 82: 3524-3529, 1993.
15. Bergamaschi, G., Rosti, V., Danova, M., Ponchio, L., Lucotti, C., and Cazzola, M. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines. Leukemia (Baltimore), 7: 2012-2018, 1993.
16. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leader, S., Freedman. M., Cohen, A., Gazit, A., Levitzki, A., and Roifman, C. M. Inhibition of recurrent human pre-B acute lymphoblastic leukemia by Jak-2 tyrosine kinase inhibitor. Nature (Lond.), 379: 645-648, 1996.
17. Bilder, A., Krawiec, J. A., Gazit, A., Gilon, C., McVety, K., Lyall, R., Zilberstein, A., Levitzki, A., Perrone, M., and Schreiber, A. B. Tyrphostins inhibit PDGF induced DNA synthesis, tyrosine specific protein kinase activity and c-fos mRNA expression in vascular smooth muscle cells. Am. J. Physiol., 260: 721-730, 1991.
18. Golomb, G., Fishbein, I., Banai, S., Mishaly, D., Moskovitz, D., Gertz., D. S., Gazit, A., Poradosu, E., and Levitzki, A. Controlled delivery of a tyrphostin inhibits neointimal hyperplasia in a rat carotid artery injury model. Atherosclerosis, 125: 171-182, 1996.
19. Ben-Bassat, H., Vardi, D., Gazit, A., Klaus, S. M., Chaova, M., Hartzstark, Z., and Levitzki, A. Tyrphostins suppress the growth of psoriatic keratinocytes. Exp. Dermatol., 4: 82-88, 1995.
20. Tweeddale, M. E., Lim, B., Jamal, N., Robinson, J., Zalcberg, J., Lockwood, G., Minden, M. D., and Messner, H. A. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood, 5: 1307-1314, 1987.
21. Yunis, J. J., Oken, N. M., Kaplan, M. E., Ensrund, K. M., Howe, R. R., and Theologides, A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphomas. N. Engl. J. Med., 307: 1231-1236, 1982.
22. Weiss, L. M., Warnke, R. A., Sklar, J., and Cleary, M. L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med., 317: 1185-1189, 1987.
23. Korsmeyer, S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood, 80: 879-886, 1992.
24. White, E. p53, guardian of Rb. Nature (Lond.), 371: 21-22, 1995.
25. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
26. Meikrantz, W., and Schlegel, R. Apoptosis and the cell cycle. J. Cell. Biochem., 58: 160-174, 1995.
27. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
28. Hirama, T., and Koeffler, P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86: 841-854, 1995.
29. Levitzki, A. Targeting signal transduction for disease therapy. Curr. Opin. Cell Biol., 8: 239-244, 1996.
30. Ben-Bassat, H., Goldblum, N., Mitrani, S., Klein, G., and Johansson, B. Concanavalin A receptors on the surface membrane of lymphocytes from patients with African Burkitt's lymphoma and lymphoma cell lines. Int. J. Cancer, 17: 448-454, 1976.
31. Ben-Bassat, H., Goldblum, N., Mitrani, S., Goldblum, T., Yoffey, J. M., Cohen, M. M., Bentwich, Z., Ramot, B., Klein, E., and Klein, G. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line DG-75). Int. J. Cancer, 19: 27-33, 1977.
32. Danova, M., Giordano, M., Mazzini, G., and Riccardi, A. Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia. Leuk. Res., 14: 417-422, 1990.
33. Gazit, A., Osherov, N., Posner, I., Yaish, R., Poradosu, E., Gilonand, C., and Levitzki, A. Tyrphostins. 2. Heterocyclic and α-substituted benzylide-nemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J. Med. Chem., 34: 1897-1907, 1991.
34. Gazit, A., Osherov, N., Posner, I., Bar-Sinai, A., Gilon, C., and Levitzki, A. Tyrphostins. 3. Structure activity relationship studies of α-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J. Med. Chem., 36: 3556-3564, 1993.
35. Telford, W. G., King, L. E., and Fraker, P. J. Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Proliferation, 24: 447-459, 1991.
36. Carbonari, M., Cibati, M., and Fiorilli, M. Measurement of apoptotic cells in peripheral blood. Cytometry, 22: 161-167, 1995.
37. Ishizaka, A., Tono-oka, T., and Matsumoto, S. Evaluation of the proliferative response of lymphocytes by measurement of intracellular ATP. J. Immunol. Methods, 72: 127-132, 1984.
38. Gillespie, J., Dye, J. F., Schachter, M., and Guillou, P. J. Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors. Br. J. Cancer, 68: 1122-1126, 1993.
39. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
40. Shi, Y., Szalay, M. G., Paskar, L., Boyer, M., Singh, B., and Green, D. R. Activation-induced cell death in T cell hybridomas is due to apoptosis: morphological aspects and DNA fragmentation. J. Immunol., 144: 3326-3333, 1990.
41. Miyashita, T., and Reed, J. C. bcl-2 gene transfer increases relative resistance of S49. 1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoid and multiple chemotherapeutic drugs. Cancer Res., 52(19): 5407-5411, 1992.
42. Alnemri, E. S., Fernandes, T. F., Haldar, S., Croce, C. M., and Litwack, G. Involvement of Bcl-2 in glucocorticoid-induccd apoptosis in human pre-B-leukemias. Cancer Res., 52: 491-495, 1992.
43. Siegel, R. M., Katsumata, M., Miyashita, T., Louie, D. C., Greene, M. I., and Reed, J. C. Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc. Natl. Acad. Sci. USA, 89: 7003-7007, 1992.
44. Caron-Leslie, L. M., Evans, R. B., and Cidlowski, J. A. Bcl-2 inhibits glucocorticoid-induced apoptosis but only partially blocks calcium ionophore or cycloheximide-regulated apoptosis in S49 cells. FASEB J., 8: 639-645, 1994.
45. Van den Bogert, C., Muus, P., Haanen, C., Pennings, A., Melis, T. E., and Kroon, A. M. Mitochondrial biogenesis and mitochondrial activity during the progression of the cell cycle of human leukemic cells. Exp. Cell Res., 178: 143-153, 1988.
46. 2+: their relationship to apoptosis and oncogenesis. FEBS Lett., 325: 104-107, 1993.
47. Wolvetang, E. J., Johnson, K. L., Krauer, K., Ralph, S. J., and Linnane, A. W. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett., 339: 40-44, 1994.
48. Young, S. W., Poole, R. C., Hudson, A. T., Halestrap, A. P., Denton, R. M., and Tavare, J. M. Effects of tyrosine kinase inhibitors on protein kinase-independent systems. FEBS Lett., 316: 278-282, 1993.
49. Terada, H., Fukui, Y., Shinohara, Y., and Ju-ichi, M. Unique action of a modified weakly acidic uncoupler without an acidic group, methylated SF 6847, as an inhibitor of oxidative phosphorylation with no uncoupling activity: possible identity of uncoupler binding protein. Biochim. Biophys. Acta, 933: 193-199, 1988.
50. Dou, Q. P., An, B., and Will, P. L. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc. Natl. Acad. Sci. USA, 92: 9019-9023, 1995.
51. Traganos, F., Ardelt, B., Halko, N., Bruno, S., and Darzynkiewicz, Z. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res., 52: 6200-6208, 1992.
52. ncu expressing non-small cell lung cancer cells. Cancer Res., 56: 1068-1064, 1996.